These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32010575)

  • 1. Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochemical markers.
    Ni J; Guo T; Li Y; Yang X; Li Y; Zou L; Chu L; Chu X; Li S; Ye L; Zhang Y; Zhu Z
    Transl Lung Cancer Res; 2019 Dec; 8(6):967-978. PubMed ID: 32010575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors of postoperative recurrence and potential candidate of adjuvant radiotherapy in lung adenosquamous carcinoma.
    Ni J; Zheng Z; Li J; Li Y; Fan M; Liu L
    J Thorac Dis; 2020 Oct; 12(10):5593-5602. PubMed ID: 33209392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
    Yang H; Wang K; Li S; Li Y; Yuan L
    Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
    [No Abstract]   [Full Text] [Related]  

  • 5. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
    Zhai H; Zhong W; Yang X; Wu YL
    Transl Lung Cancer Res; 2015 Feb; 4(1):82-93. PubMed ID: 25806348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
    Zhao P; Zhen H; Zhao H; Zhao L; Cao B
    BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients.
    Chen RL; Sun LL; Cao Y; Chen HR; Zhou JX; Gu CY; Zhang Y; Wang SY; Hou W; Lin LZ
    Front Oncol; 2021; 11():629394. PubMed ID: 33912453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study.
    Liu JF; Sun XS; Yin JH; Xu XE
    Front Oncol; 2023; 13():1132854. PubMed ID: 36994198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
    Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
    Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy for patients with completely resected pathologic IIIA(N2) non-small-cell lung cancer: a retrospective analysis.
    Zhu Y; Fu L; Jing W; Kong L; Yu J
    Cancer Manag Res; 2019; 11():10901-10908. PubMed ID: 32021415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
    Wen M; Wang L; Wang X; Yang S; Sun Y; Xia J; Zhang Y; Zhang Z; Huang L; Jiang T
    Oncol Res Treat; 2020; 43(12):686-693. PubMed ID: 33197924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
    Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
    Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Adjuvant Setting for Patients with Resected Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer: A Meta-Analysis with 11 Trials.
    Yin Q; Xun X; Yang G; Cui H; Liu H
    Oncol Res Treat; 2021; 44(6):344-353. PubMed ID: 33951671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between clinicopathological factors and postoperative radiotherapy in patients with completely resected pathological N2 non-small cell lung cancer.
    Xu Y; Li J; Wang J; Hu X; Ma H; Li P; Zheng X; Chen M
    Oncol Lett; 2018 Feb; 15(2):2641-2650. PubMed ID: 29434986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer.
    Liu SM; Chen C; Zhang YK; Zhong WZ; Wu YL; Liu SY; Li Y
    Biomark Res; 2023 Mar; 11(1):26. PubMed ID: 36879350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supraclavicular Recurrence in Completely Resected (y)pN2 Non-Small Cell Lung Cancer: Implications for Postoperative Radiotherapy.
    Liu L; Zheng Z; Li J; Li Y; Ni J
    Front Oncol; 2020; 10():1414. PubMed ID: 32850456
    [No Abstract]   [Full Text] [Related]  

  • 17. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
    Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Wei YC; Liu YY; Chen C; Cheng Y; Yin R; Yang F; Ren SX; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yang JJ; Yan HH; Yang XN; Liu SY; Zhou Q; Wu YL
    J Clin Oncol; 2021 Mar; 39(7):713-722. PubMed ID: 33332190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
    Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
    J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
    [No Abstract]   [Full Text] [Related]  

  • 20. EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials.
    Wu JX; He Q; Ye F; Zhou QX; Chen HJ; Sun L; Wu H
    Onco Targets Ther; 2018; 11():6803-6810. PubMed ID: 30349313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.